To amend title XI of the Social Security Act to clarify manufacturer transparency reporting requirements for certain transfers used for educational purposes.

Issues related to the healthcare workforce. Issues relating to consumer directed health information exchange, interoperability, information blocking, and patient access to health information. Issues relating to the impact of potential privacy legislation on Health Insurance Portability and Accountability Act (PL 104-191) and medical research. PL 116-260 Division BB Title I, No Surprises Act, provisions related to provider exchange network accuracy. Clarifying the patient education exclusion provision of the CMS Open Payments Program. Promotion of Title VIII of the Public Health Services Act including transition to practice; diversity, equity and inclusion; reducing workforce shortages. HR 4402, to clarify manufacturer transparency reporting requirements for certain transfers used for educational purposes, all provisions. Issues related to the education and awareness of the benefits of using real world data in healthcare research and development. Issues related to the Cancer Moonshot Initiative. Issues related to the White House Initiative on Women's Health Research and Executive Order on Women's Health Research and Innovation (EO 14120). Raising awareness of the use of artificial intelligence in healthcare, health education and research and development. Issues related to the CMS waiver of asset testing for Medicaid recipients. Issues related to tax credits for the federally operated health insurance exchange.

Client expense: $700,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R.4402 - To amend title XI of the Social Security Act to clarify manufacturer transparency reporting requirements for certain transfers used for educational purposes, specifying that manufacturers of drugs, devices, biologics, or medical supplies covered by Medicare, Medicaid or the Children's Health Insurance Program (CHIP) are not required to report peer-reviewed journals, journal reprints, journal supplements, medical conference reports, or medical textbooks that are provided to health care practitioners or teaching hospitals. H.R.8818 - American Privacy Rights Act of 2024 (APRA) to provide Americans with foundational data privacy rights, create strong oversight mechanisms, and establish meaningful enforcement.

Client expense: Not reported · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES

H.R.4402 - To amend title XI of the Social Security Act to clarify manufacturer transparency reporting requirements for certain transfers used for educational purposes, specifying that manufacturers of drugs, devices, biologics, or medical supplies covered by Medicare, Medicaid or the Children's Health Insurance Program (CHIP) are not required to report peer-reviewed journals, journal reprints, journal supplements, medical conference reports, or medical textbooks that are provided to health care practitioners or teaching hospitals.

Client expense: Not reported · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES

Lobby members of Congress regarding issues related to telemedicine. Advocate for a stable supply of medications and for mitigation of drug shortages, including lidocaine. Advocate for increased transparency regarding drug pricing. Advocate for reducing barriers to entry of generic drugs into the marketplace. Advocate for transparency on the part of pharmaceutical benefit managers. Advocate for patient access to compounded medications. Advocate for reducing the burdens of utilization management tools, including step therapy and prior authorization for pharmaceuticals and services. Advocate for a stable supply of medications and mitigate drug shortages. Lobby members of the House to join the Congressional Skin Cancer Caucus. Advocate for adequate and accurate network coverage for dermatologic care within health insurance exchange networks. Support H.R. 2630/S. 652, Safe Step Act. Advocate for relief from prior authorization requirements under Medicare Advantage and Medicare Part D plans. Advocate for the continued and increased funding of Community Health Centers. Advocate for implementation of surprise medical billing legislation (enacted as part of P.L. 116-260, Consolidated Appropriations Act, 2021, H.R. 133) as intended by Congress. Support H.R. 5894/S. 2624. Support H.R. 1202/S. 704, Resident Education Deferred Interest Act or the REDI Act Support H.R. 2389/S1032, the Resident Physician Shortage Reduction Act Lobbied Congress on physician workforce, administrative burden, and workforce diversity issues Advocate for the FDA to implement the 2015 rule, General and Plastic Surgery Devices: Restricted Sale, Distribution, and Use of Sunlamp Products; and the Sunlamp Products Proposed; Amendment to Performance Standard, which would ban minors under the age of 18 from using tanning beds. Advocate for implementation of language to direct the Secretary of Health and Human Services to open a public docket for the submission of public comments regarding factors that should be taken into consideration when reviewing a proposed modification to an approved risk evaluation and mitigation strategy, and for other purposes (enacted as part of P.L. 117-328, Consolidated Appropriations Act, 2023, H.R. 2617). Advocate to replace scheduled and anticipated cuts in Medicare payments with positive, inflationary-based updates, eliminate the anticipated conversion factor cut in the CMS proposed rule for the 2024 Medicare Physician Fee Schedule (MPFS) associated with budget neutrality adjustments tied to Evaluation & Management (E/M) Code MPFS policy changes Advocate against H.R 618, Improving Access to Workers Compensation for Injured Federal Workers Act, which expands the role of nurse practitioners and physician assistants in providing services to injured federal workers under the federal workers' compensation program. Lobbied Congress on impact of the burden of small business issues impacting small physician practices, including Medicare reimbursement cuts. Advocate for H. Res. 365, in support of efforts to curb the incidences of skin cancer beginning with childhood skin protection. Support H.R.2474, Strengthening Medicare for Patients and Providers Act. Support H.R. 2761, S. 705, Specialty Physicians Advancing Rural Care Act (SPARC Act). Support H.R. 4402, Protecting and Continuing Physician Education and Patient Care Act Support H.R. 830/S. 1375, the Help Ensure Lower Patient (HELP) Copays Act. Support H.R. 3674, the Providing Relief and Stability for Medicare Patients Act of 2023. Support S. 935, the Fair Accountability & Innovative Research (FAIR) Drug Pricing Act. Support H.R. 4968, Getting Over Lengthy Delays in Care as Required by Doctors (GOLD CARD) Act. Support H.R.2389/S.1302, the Resident Physicians Shortage Reduction Act. Advocate regarding matters related to Merit-based Incentive Payment System (MIPS), MIPS Value Pathways (MVPs), and Qualified Clinical Data Registries. Advocate regarding AADA efforts in skin cancer prevention and AADA skin cancer prevention programs and initiatives. H.R.7153/S.3679, the Dr. Lorna Breen Health Care Provider Protection Reauthorization Act. S.Res.567/H.Res.1089, a resolution recognizing the seriousness of widespread health care worker burnout in the United States and the need to strengthen health workforce well-being, and expressing support for the designation of March 18, 2024, as the inaugural "Health Workforce Well-Being Day of Awareness".

Issues related to the healthcare workforce. Issues relating to consumer directed health information exchange, interoperability, information blocking, and patient access to health information. Issues relating to the impact of potential privacy legislation on Health Insurance Portability and Accountability Act and medical research. PL 116-260 Division BB Title I, No Surprises Act, provisions related to provider exchange network accuracy. Clarifying the patient education exclusion provision of the CMS Open Payments Program. Promotion of Title VIII of the Public Health Services Act including transition to practice; diversity, equity and inclusion; reducing workforce shortages. HR 4402, to clarify manufacturer transparency reporting requirements for certain transfers used for educational purposes, all provisions. Issues related to the education and awareness of the benefits of using real world data in healthcare research and development. Issues related to the Cancer Moonshot Initiative. Issues related to the White House Initiative on Women's Health Research and Executive Order on Women's Health Research and Innovation. Raising awareness of the use of AI in healthcare, health education and research and development. Issues related to the CMS waiver of asset testing for Medicaid recipients in CA.

Client expense: $800,000 · Firm income: Not reported

Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Office of Science & Technology Policy (OSTP), SENATE

H.R.4402 - To amend title XI of the Social Security Act to clarify manufacturer transparency reporting requirements for certain transfers used for educational purposes, specifying that manufacturers of drugs, devices, biologics, or medical supplies covered by Medicare, Medicaid or the Children's Health Insurance Program (CHIP) are not required to report peer-reviewed journals, journal reprints, journal supplements, medical conference reports, or medical textbooks that are provided to health care practitioners or teaching hospitals.

Client expense: Not reported · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES

Issues related to the healthcare workforce. Issues relating to consumer directed health information exchange, interoperability, information blocking, and patient access to health information. Issues relating to the impact of potential privacy legislation on Health Insurance Portability and Accountability Act and medical research. PL 116-260 Division BB Title I, No Surprises Act, provisions related to provider exchange network accuracy. Clarifying the patient education exclusion provision of the CMS Open Payments Program. Promotion of Title VIII of the Public Health Services Act including transition to practice; diversity, equity and inclusion; reducing workforce shortages. HR 4402, to clarify manufacturer transparency reporting requirements for certain transfers used for educational purposes, all provisions. Issues related to the education and awareness of the benefits of using real world data in healthcare research and development. Issues related to the Cancer Moonshot Initiative. Issues related to the White House Initiative on Women's Health Research and Executive Order on Women's Health Research and Innovation. Raising awareness of the use of AI in healthcare, health education and research and development. Issues related to the CMS waiver of asset testing for Medicaid recipients in CA.

Client expense: $760,000 · Firm income: Not reported

Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Office of Science & Technology Policy (OSTP), SENATE

Lobby members of Congress regarding issues related to telemedicine. Advocate for a stable supply of medications and for mitigation of drug shortages, including lidocaine. Advocate for increased transparency regarding drug pricing. Advocate for reducing barriers to entry of generic drugs into the marketplace. Advocate for transparency on the part of pharmaceutical benefit managers. Advocate for patient access to compounded medications. Advocate for reducing the burdens of utilization management tools, including step therapy and prior authorization for pharmaceuticals and services. Advocate for a stable supply of medications and mitigate drug shortages. Lobby members of the House to join the Congressional Skin Cancer Caucus. Advocate for adequate and accurate network coverage for dermatologic care within health insurance exchange networks. Support H.R. 2630/S. 652, Safe Step Act. Advocate for relief from prior authorization requirements under Medicare Advantage and Medicare Part D plans. Advocate for the continued and increased funding of Community Health Centers. Advocate for implementation of surprise medical billing legislation (enacted as part of P.L. 116-260, Consolidated Appropriations Act, 2021, H.R. 133) as intended by Congress. Support H.R. 5894/S. 2624. Support H.R. 1202/S. 704, Resident Education Deferred Interest Act or the REDI Act Support H.R. 2389/S1032, the Resident Physician Shortage Reduction Act Lobbied Congress on physician workforce, administrative burden, and workforce diversity issues Advocate for the FDA to implement the 2015 rule, General and Plastic Surgery Devices: Restricted Sale, Distribution, and Use of Sunlamp Products; and the Sunlamp Products Proposed; Amendment to Performance Standard, which would ban minors under the age of 18 from using tanning beds. Advocate for implementation of language to direct the Secretary of Health and Human Services to open a public docket for the submission of public comments regarding factors that should be taken into consideration when reviewing a proposed modification to an approved risk evaluation and mitigation strategy, and for other purposes (enacted as part of P.L. 117-328, Consolidated Appropriations Act, 2023, H.R. 2617). Advocate to replace scheduled and anticipated cuts in Medicare payments with positive, inflationary-based updates, eliminate the anticipated conversion factor cut in the CMS proposed rule for the 2024 Medicare Physician Fee Schedule (MPFS) associated with budget neutrality adjustments tied to Evaluation & Management (E/M) Code MPFS policy changes Advocate against H.R 618, Improving Access to Workers Compensation for Injured Federal Workers Act, which expands the role of nurse practitioners and physician assistants in providing services to injured federal workers under the federal workers' compensation program. Lobbied Congress on impact of the burden of small business issues impacting small physician practices, including Medicare reimbursement cuts. Advocate for H. Res. 365, in support of efforts to curb the incidences of skin cancer beginning with childhood skin protection. Support H.R.2474, Strengthening Medicare for Patients and Providers Act. Support H.R. 2761, S. 705, Specialty Physicians Advancing Rural Care Act (SPARC Act). Support H.R. 4402, Protecting and Continuing Physician Education and Patient Care Act Support H.R. 830/S. 1375, the Help Ensure Lower Patient (HELP) Copays Act. Support H.R. 3674, the Providing Relief and Stability for Medicare Patients Act of 2023. Support S. 935, the Fair Accountability & Innovative Research (FAIR) Drug Pricing Act. Support H.R. 4968, Getting Over Lengthy Delays in Care as Required by Doctors (GOLD CARD) Act. Support H.R.2389/S.1302, the Resident Physicians Shortage Reduction Act. Advocate regarding matters related to Merit-based Incentive Payment System (MIPS), MIPS Value Pathways (MVPs), and Qualified Clinical Data Registries. Advocate regarding AADA efforts in skin cancer prevention and AADA skin cancer prevention programs and initiatives. H.R.7153/S.3679, the Dr. Lorna Breen Health Care Provider Protection Reauthorization Act. S.Res.567/H.Res.1089, a resolution recognizing the seriousness of widespread health care worker burnout in the United States and the need to strengthen health workforce well-being, and expressing support for the designation of March 18, 2024, as the inaugural "Health Workforce Well-Being Day of Awareness".

H.R.4402 - To amend title XI of the Social Security Act to clarify manufacturer transparency reporting requirements for certain transfers used for educational purposes, specifying that manufacturers of drugs, devices, biologics, or medical supplies covered by Medicare, Medicaid or the Children's Health Insurance Program (CHIP) are not required to report peer-reviewed journals, journal reprints, journal supplements, medical conference reports, or medical textbooks that are provided to health care practitioners or teaching hospitals.

Client expense: Not reported · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES

Lobby members of Congress regarding issues related to telemedicine. Advocate for a stable supply of medications and for mitigation of drug shortages, including lidocaine. Advocate for increased transparency regarding drug pricing. Advocate for reducing barriers to entry of generic drugs into the marketplace. Advocate for transparency on the part of pharmaceutical benefit managers. Advocate for patient access to compounded medications. Advocate for reducing the burdens of utilization management tools, including step therapy and prior authorization for pharmaceuticals and services. Advocate for a stable supply of medications and mitigate drug shortages. Lobby members of the House to join the Congressional Skin Cancer Caucus. Advocate for adequate and accurate network coverage for dermatologic care within health insurance exchange networks. Support H.R. 2630/S. 652, Safe Step Act. Advocate for relief from prior authorization requirements under Medicare Advantage and Medicare Part D plans. Advocate for the continued and increased funding of Community Health Centers. Advocate for implementation of surprise medical billing legislation (enacted as part of P.L. 116-260, Consolidated Appropriations Act, 2021, H.R. 133) as intended by Congress. Support H.R. 5894/S. 2624. Support H.R. 1202/S. 704, Resident Education Deferred Interest Act or the REDI Act Support H.R. 2389/S1032, the Resident Physician Shortage Reduction Act Lobbied Congress on physician workforce, administrative burden, and workforce diversity issues Advocate for the FDA to implement the 2015 rule, General and Plastic Surgery Devices: Restricted Sale, Distribution, and Use of Sunlamp Products; and the Sunlamp Products Proposed; Amendment to Performance Standard, which would ban minors under the age of 18 from using tanning beds. Advocate for implementation of language to direct the Secretary of Health and Human Services to open a public docket for the submission of public comments regarding factors that should be taken into consideration when reviewing a proposed modification to an approved risk evaluation and mitigation strategy, and for other purposes (enacted as part of P.L. 117-328, Consolidated Appropriations Act, 2023, H.R. 2617). Advocate to replace scheduled and anticipated cuts in Medicare payments with positive, inflationary-based updates, eliminate the anticipated conversion factor cut in the CMS proposed rule for the 2024 Medicare Physician Fee Schedule (MPFS) associated with budget neutrality adjustments tied to Evaluation & Management (E/M) Code MPFS policy changes Advocate against H.R 618, Improving Access to Workers Compensation for Injured Federal Workers Act, which expands the role of nurse practitioners and physician assistants in providing services to injured federal workers under the federal workers' compensation program. Lobbied Congress on impact of the burden of small business issues impacting small physician practices, including Medicare reimbursement cuts. Advocate for H. Res. 365, in support of efforts to curb the incidences of skin cancer beginning with childhood skin protection. Support H.R.2474, Strengthening Medicare for Patients and Providers Act. Support H.R. 2761, S. 705, Specialty Physicians Advancing Rural Care Act (SPARC Act). Support H.R. 4402, Protecting and Continuing Physician Education and Patient Care Act Support H.R. 830/S. 1375, the Help Ensure Lower Patient (HELP) Copays Act. Support H.R. 3674, the Providing Relief and Stability for Medicare Patients Act of 2023. Support S. 935, the Fair Accountability & Innovative Research (FAIR) Drug Pricing Act. Support H.R. 4968, Getting Over Lengthy Delays in Care as Required by Doctors (GOLD CARD) Act. Support H.R.2389/S.1302, the Resident Physicians Shortage Reduction Act. Advocate regarding matters related to Merit-based Incentive Payment System (MIPS), MIPS Value Pathways (MVPs), and Qualified Clinical Data Registries. Advocate regarding AADA efforts in skin cancer prevention and AADA skin cancer prevention programs and initiatives.

Issues related to the healthcare workforce. Issues relating to consumer directed health information exchange, interoperability, information blocking, and patient access to health information. Issues relating to the impact of potential privacy legislation on Health Insurance Portability and Accountability Act and medical research. PL 116-260 Division BB Title I, No Surprises Act, provisions related to provider exchange network accuracy. Clarifying the patient education exclusion provision of the CMS Open Payments Program. Promotion of Title VIII of the Public Health Services Act including transition to practice; diversity, equity and inclusion; reducing workforce shortages. HR 4402, to clarify manufacturer transparency reporting requirements for certain transfers used for educational purposes, all provisions. Issues related to the education and awareness of the benefits of using real world data in healthcare research and development. Issues related to the Cancer Moonshot Initiative.

Client expense: $810,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to the healthcare workforce. Issues relating to consumer directed health information exchange, interoperability, information blocking, and patient access to health information. Potential privacy legislation impact on Health Insurance Portability and Accountability Act and medical research. PL 116-260 Division BB Title I, No Surprises Act, provisions related to provider exchange network accuracy. Clarifying the patient education exclusion provision of the CMS Open Payments Program. Promotion of Title VIII of the Public Health Services Act including transition to practice; diversity, equity and inclusion; reducing workforce shortages. HR 4402, to clarify manufacturer transparency reporting requirements for certain transfers used for educational purposes, all provisions.

Client expense: $820,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Lobby members of Congress regarding issues related to telemedicine. Advocate for a stable supply of medications and for mitigation of drug shortages, including lidocaine. Advocate for increased transparency regarding drug pricing. Advocate for reducing barriers to entry of generic drugs into the marketplace. Advocate for transparency on the part of pharmaceutical benefit managers. Advocate for patient access to compounded medications. Advocate for reducing the burdens of utilization management tools, including step therapy and prior authorization for pharmaceuticals and services. Advocate for a stable supply of medications and mitigate drug shortages. Lobby members of the House to join the Congressional Skin Cancer Caucus. Advocate for adequate and accurate network coverage for dermatologic care within health insurance exchange networks. Support H.R. 2630/S. 652, Safe Step Act. Advocate for relief from prior authorization requirements under Medicare Advantage and Medicare Part D plans. Advocate for the continued and increased funding of Community Health Centers. Advocate for implementation of surprise medical billing legislation (enacted as part of P.L. 116-260, Consolidated Appropriations Act, 2021, H.R. 133) as intended by Congress. Support H.R. 5894/S. 2624. Support H.R. 1202/S. 704, Resident Education Deferred Interest Act or the REDI Act Support H.R. 2389/S1032, the Resident Physician Shortage Reduction Act Lobbied Congress on physician workforce, administrative burden, and workforce diversity issues Advocate for the FDA to implement the 2015 rule, General and Plastic Surgery Devices: Restricted Sale, Distribution, and Use of Sunlamp Products; and the Sunlamp Products Proposed; Amendment to Performance Standard, which would ban minors under the age of 18 from using tanning beds. Advocate for implementation of language to direct the Secretary of Health and Human Services to open a public docket for the submission of public comments regarding factors that should be taken into consideration when reviewing a proposed modification to an approved risk evaluation and mitigation strategy, and for other purposes (enacted as part of P.L. 117-328, Consolidated Appropriations Act, 2023, H.R. 2617). Advocate to replace scheduled and anticipated cuts in Medicare payments with positive, inflationary-based updates, eliminate the anticipated conversion factor cut in the CMS proposed rule for the 2024 Medicare Physician Fee Schedule (MPFS) associated with budget neutrality adjustments tied to Evaluation & Management (E/M) Code MPFS policy changes Advocate against H.R 618, Improving Access to Workers Compensation for Injured Federal Workers Act, which expands the role of nurse practitioners and physician assistants in providing services to injured federal workers under the federal workers' compensation program. Lobbied Congress on impact of the burden of small business issues impacting small physician practices, including Medicare reimbursement cuts. Advocate for H. Res. 365, in support of efforts to curb the incidences of skin cancer beginning with childhood skin protection. Support H.R.2474, Strengthening Medicare for Patients and Providers Act. Support H.R. 2761, S. 705, Specialty Physicians Advancing Rural Care Act (SPARC Act). Support H.R. 4402, Protecting and Continuing Physician Education and Patient Care Act Support H.R. 830/S. 1375, the Help Ensure Lower Patient (HELP) Copays Act. Support H.R. 3674, the Providing Relief and Stability for Medicare Patients Act of 2023. Support S. 935, the Fair Accountability & Innovative Research (FAIR) Drug Pricing Act. Support H.R. 4968, Getting Over Lengthy Delays in Care as Required by Doctors (GOLD CARD) Act. Support H.R.2389/S.1302, the Resident Physicians Shortage Reduction Act. Advocate regarding matters related to Merit-based Incentive Payment System (MIPS), MIPS Value Pathways (MVPs), and Qualified Clinical Data Registries. Advocate regarding AADA efforts in skin cancer prevention and AADA skin cancer prevention programs and initiatives.

Lobby members of Congress regarding issues related to telemedicine. Advocate for a stable supply of medications and for mitigation of drug shortages, including lidocaine. Advocate for increased transparency regarding drug pricing. Advocate for reducing barriers to entry of generic drugs into the marketplace. Advocate for transparency on the part of pharmaceutical benefit managers. Advocate for patient access to compounded medications. Advocate for reducing the burdens of utilization management tools, including step therapy and prior authorization for pharmaceuticals and services. Advocate for a stable supply of medications and mitigate drug shortages. Lobby members of the House to join the Congressional Skin Cancer Caucus. Advocate for adequate and accurate network coverage for dermatologic care within health insurance exchange networks. Support H.R. 2630/S. 652, Safe Step Act. Support S. 127, Pharmacy Benefit Manager Transparency Act Advocate for relief from prior authorization requirements under Medicare Advantage and Medicare Part D plans. Advocate for the continued and increased funding of Community Health Centers. Advocate for implementation of surprise medical billing legislation (enacted as part of P.L. 116-260, Consolidated Appropriations Act, 2021, H.R. 133) as intended by Congress. Support H.R. 1202/S. 704, Resident Education Deferred Interest Act or the REDI Act Support the Resident Physician Shortage Reduction Act (S.1302/H.R. 2389) Lobbied Congress on physician workforce, administrative burden, and workforce diversity issues Advocate for the FDA to implement the 2015 rule, General and Plastic Surgery Devices: Restricted Sale, Distribution, and Use of Sunlamp Products; and the Sunlamp Products Proposed; Amendment to Performance Standard, which would ban minors under the age of 18 from using tanning beds. Advocate for implementation of language to direct the Secretary of Health and Human Services to open a public docket for the submission of public comments regarding factors that should be taken into consideration when reviewing a proposed modification to an approved risk evaluation and mitigation strategy, and for other purposes (enacted as part of P.L. 117-328, Consolidated Appropriations Act, 2023, H.R. 2617). Advocate to replace scheduled and anticipated cuts in Medicare payments with positive, inflationary-based updates, eliminate the anticipated conversion factor cut in the CMS proposed rule for the 2024 Medicare Physician Fee Schedule (MPFS) associated with budget neutrality adjustments tied to Evaluation & Management (E/M) Code MPFS policy changes Advocate against H.R 618, Improving Access to Workers Compensation for Injured Federal Workers Act, which expands the role of nurse practitioners and physician assistants in providing services to injured federal workers under the federal workers' compensation program. Lobbied Congress on impact of the burden of small business issues impacting small physician practices, including Medicare reimbursement cuts. Advocate for H. Res. 365, in support of efforts to curb the incidences of skin cancer beginning with childhood skin protection. Support H.R.2474, Strengthening Medicare for Patients and Providers Act. Support H.R. 2761, S. 705, Specialty Physicians Advancing Rural Care Act (SPARC Act). Support H.R. 4402, Protecting and Continuing Physician Education and Patient Care Act Support H.R. 830/S. 1375, the Help Ensure Lower Patient (HELP) Copays Act. Support H.R. 3674, the Providing Relief and Stability for Medicare Patients Act of 2023. Support S. 935, the Fair Accountability & Innovative Research (FAIR) Drug Pricing Act. Advocate regarding matters related to Merit-based Incentive Payment System (MIPS), MIPS Value Pathways (MVPs), and Qualified Clinical Data Registries. Advocate regarding AADA efforts in skin cancer prevention and AADA skin cancer prevention programs and initiatives.

S.230/H.R. 834: To support rural residency training funding that is equitable for all States S.470/H.R.977, Patient Access to Higher Quality Health Care Act: To repeal changes made by health care reform laws to the Medicare exception to the prohibition on certain physician referrals for hospitals. H.R.751, Fair Access in Residency (FAIR) Act: To encourage more equitable treatment of osteopathic and allopathic candidates in the residency application and review process. H.R.2389, Resident Physician Shortage Reduction Act: To provide for the distribution of additional residency positions H.R. 2474, Strengthening Medicare for Patients and Providers Act: To provide an update to a single conversion factor under the Medicare physician fee schedule that is based on the Medicare economic index. H.R. 2713, the Improving Care and Access to Nurses Act: To increase access to services provided by advanced practice registered nurses under the Medicare and Medicaid programs. H.R.4402, Sunshine Act of 2023: To clarify manufacturer transparency reporting requirements for certain transfers used for educational purposes. No bill: Medicare physician payment reforms including modifications to budget neutrality and the Quality Payment Program. No bill: Prior authorization reform legislation in Medicare Advantage.

Client expense: $35,000 · Firm income: Not reported

S.230/H.R. 834: To support rural residency training funding that is equitable for all States S.470/H.R.977, Patient Access to Higher Quality Health Care Act: To repeal changes made by health care reform laws to the Medicare exception to the prohibition on certain physician referrals for hospitals. H.R.751, Fair Access in Residency (FAIR) Act: To encourage more equitable treatment of osteopathic and allopathic candidates in the residency application and review process. H.R.2389, Resident Physician Shortage Reduction Act: To provide for the distribution of additional residency positions H.R. 2474, Strengthening Medicare for Patients and Providers Act: To provide an update to a single conversion factor under the Medicare physician fee schedule that is based on the Medicare economic index. H.R. 2713, the Improving Care and Access to Nurses Act: To increase access to services provided by advanced practice registered nurses under the Medicare and Medicaid programs H.R.4402, Sunshine Act of 2023:To clarify manufacturer transparency reporting requirements for certain transfers used for educational purposes No bill: Medicare physician payment reforms including modifications to budget neutrality and the Quality Payment Programm No bill: Prior authorization reform legislation in Medicare Advantage

Client expense: $35,000 · Firm income: Not reported

Lobby members of Congress regarding issues related to telemedicine. Advocate for a stable supply of medications and for mitigation of drug shortages, including lidocaine. Advocate for increased transparency regarding drug pricing. Advocate for reducing barriers to entry of generic drugs into the marketplace. Advocate for transparency on the part of pharmaceutical benefit managers. Advocate for patient access to compounded medications. Advocate for reducing the burdens of utilization management tools, including step therapy and prior authorization for pharmaceuticals and services. Advocate for a stable supply of medications and mitigate drug shortages. Lobby members of the House to join the Congressional Skin Cancer Caucus. Advocate for adequate and accurate network coverage for dermatologic care within health insurance exchange networks. Support H.R. 2630/S. 652, Safe Step Act. Support S. 127, Pharmacy Benefit Manager Transparency Act Advocate for relief from prior authorization requirements under Medicare Advantage and Medicare Part D plans. Advocate for the continued and increased funding of Community Health Centers. Advocate for implementation of surprise medical billing legislation (enacted as part of P.L. 116-260, Consolidated Appropriations Act, 2021, H.R. 133) as intended by Congress. Support H.R. 1202/S. 704, Resident Education Deferred Interest Act or the REDI Act Support the Resident Physician Shortage Reduction Act (S.1302/H.R. 2389) Lobbied Congress on physician workforce, administrative burden, and workforce diversity issues Advocate for the FDA to implement the 2015 rule, General and Plastic Surgery Devices: Restricted Sale, Distribution, and Use of Sunlamp Products; and the Sunlamp Products Proposed; Amendment to Performance Standard, which would ban minors under the age of 18 from using tanning beds. Advocate for implementation of language to direct the Secretary of Health and Human Services to open a public docket for the submission of public comments regarding factors that should be taken into consideration when reviewing a proposed modification to an approved risk evaluation and mitigation strategy, and for other purposes (enacted as part of P.L. 117-328, Consolidated Appropriations Act, 2023, H.R. 2617). Advocate to replace scheduled and anticipated cuts in Medicare payments with positive, inflationary-based updates, eliminate the anticipated conversion factor cut in the CMS proposed rule for the 2024 Medicare Physician Fee Schedule (MPFS) associated with budget neutrality adjustments tied to Evaluation & Management (E/M) Code MPFS policy changes Advocate against H.R 618, Improving Access to Workers Compensation for Injured Federal Workers Act, which expands the role of nurse practitioners and physician assistants in providing services to injured federal workers under the federal workers' compensation program. Lobbied Congress on impact of the burden of small business issues impacting small physician practices, including Medicare reimbursement cuts. Advocate for H. Res. 365, in support of efforts to curb the incidences of skin cancer beginning with childhood skin protection. Support H.R.2474, Strengthening Medicare for Patients and Providers Act. Support H.R. 2761, S. 705, Specialty Physicians Advancing Rural Care Act (SPARC Act). Support H.R. 4402, Protecting and Continuing Physician Education and Patient Care Act Support H.R. 830/S. 1375, the Help Ensure Lower Patient (HELP) Copays Act. Support H.R. 3674, the Providing Relief and Stability for Medicare Patients Act of 2023. Support S. 935, the Fair Accountability & Innovative Research (FAIR) Drug Pricing Act. Advocate regarding matters related to Merit-based Incentive Payment System (MIPS), MIPS Value Pathways (MVPs), and Qualified Clinical Data Registries. Advocate regarding AADA efforts in skin cancer prevention and AADA skin cancer prevention programs and initiatives.